Supporting discoveries include, but are not limited to, (1) high-dose hypofractionation-induced immunogenic tumor cell necrosis enhances cross-presentation of tumor antigen by dendritic cells to CD8+ T-cells in draining lymph nodes and (2) survival of cross-primed anti-tumor CD8+ T-cells from cell death by radiation, as hypofractionated radiotherapy is likely to be completed before the migration of these radiosensitive lymphocytes to infiltrate tumor mass [16]. The gene discussed is CD8A; the disease is neoplasm.